The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
Open accessAbstract
Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is a rare X-linked recessive disease caused by deficiency of the lysosomal enzyme iduronate-2-sulphatase, leading to progressive accumulation of glycosaminoglycans in nearly all cell types, tissues and organs. Clinical manifestations include severe airway obstruction, skeletal deformities, cardiomyopathy and, in most patients, neurological decline. Death usually occurs in the second decade of life, although some patients with less severe disease have survived into their fifth or sixth decade. Until recently, there has been no effective therapy for MPS II, and care has been palliative. Enzyme replacement therapy (ERT) with recombinant human iduronate-2-sulphatase (idursulfase), however, has now been introduced. Weekly intravenous infusions of idursulfase have been shown to improve many of the signs and symptoms and overall wellbeing in patients with MPS II. This paper provides an overview of the clinical manifestations, diagnosis and symptomatic management of patients with MPS II and provides recommendations for the use of ERT. The issue of treating very young patients and those with CNS involvement is also discussed. ERT with idursulfase has the potential to benefit many patients with MPS II, especially if started early in the course of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The frequency of lysosomal storage diseases in The Netherlands
Poorthuis, B. J. H. M., Wevers, R. A., Kleijer, W. J., Groener, J. E. M., de Jong, J. G. N., van Weely, S., Niezen-Koning, K. E., & van Diggelen, O. P. (1999) · Human Genetics · doi:10.1007/s004390051078 · Cited by 720
Muenzer, J., Wraith, J. E., Beck, M., Giugliani, R., Harmatz, P., Eng, C. M., Vellodi, A., Martin, R., Ramaswami, U., Gucsavas-Calikoglu, M., et al. (2006) · Genetics in Medicine · doi:10.1097/01.gim.0000232477.37660.fb · Cited by 584
Self-citationCase Report and Review of Literature
Maher, A. A., & Hennawy, A. E. (1994) · Cited by 413
A Rare Disease in Two Brothers
Hunter, C. (1917) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591571701001833 · Cited by 280
Muenzer, J., Gucsavas-Calikoglu, M., McCandless, S. E., Schuetz, T. J., & Kimura, A. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.09.001 · Cited by 223
Bondeson, M.-L., Dahl, N., Malmgren, H., Kleijer, W. J., Tönnesen, T., Carlberg, B.-M., & Pettersson, U. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.4.615 · Cited by 175
Long‐term follow‐up following bone marrow transplantation for Hunter disease
Vellodi, A., Young, E., Cooper, A., Lidchi, V., Winchester, B., & Wraith, J. E. (1999) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005525931994 · Cited by 166
Self-citationLarge animal models and gene therapy
Casal, M. L., & Haskins, M. E. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201535 · Cited by 152
Otorhinolaryngological manifestations of the mucopolysaccharidoses
Simmons, M., Bruce, I. A., Penney, S., Wraith, E., & Rothera, M. (2005) · International Journal of Pediatric Otorhinolaryngology · doi:10.1016/j.ijporl.2005.01.017 · Cited by 136
Disordered breathing during sleep in patients with mucopolysaccharidoses
Leighton, S. E. J., Papsin, B. C., Vellodi, A., Dinwiddie, R., & Lane, R. (2001) · International Journal of Pediatric Otorhinolaryngology · doi:10.1016/s0165-5876(01)00417-7 · Cited by 124
Cited by
Pastores, G. M. (2012) · Swaiman's Pediatric Neurology · doi:10.1016/b978-1-4377-0435-8.00036-6 · Cited by 633
Ullman, J. C., Arguello, A., Getz, J. A., Bhalla, A., Mahon, C. S., Wang, J., Giese, T., Bedard, C., Kim, D. J., Blumenfeld, J. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1163 · Cited by 205
Pardridge, W. M. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.952627 · Cited by 152
Oxidative stress in developmental brain disorders
Hayashi, M., Miyata, R., & Tanuma, N. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-0653-2_21 · Cited by 56
Syndromic retinitis pigmentosa.
Karuntu, J. S., Almushattat, H., Nguyen, X.-T.-A., Plomp, A. S., Wanders, R. J. A., Hoyng, C. B., van Schooneveld, M. J., Schalij-Delfos, N. E., Brands, M. M., Leroy, B. P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101324 · Cited by 39
Metadata
- Authors
- Wraith, J. E., Scarpa, M., Beck, M., Bodamer, O. A., De Meirleir, L., Guffon, N., Meldgaard Lund, A., Malm, G., Van der Ploeg, A. T., & Zeman, J.
- Venue
- European Journal of Pediatrics
- Published
- 2007-11-23
- Volume
- 167
- Issue
- 3
- Pages
- 267-277
- ISSN
- 0340-6199 (ISSN-L)
- 1432-1076
- OpenAlex
- W2117500144
- Cited by
- 536
- References
- 17
- FWCI
- 9.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. https://app.cochat.ai/papers/10.1007/s00431-007-0635-4
- The paper
- Wraith, J. E., Scarpa, M., Beck, M., Bodamer, O. A., De Meirleir, L., Guffon, N., Meldgaard Lund, A., Malm, G., Van der Ploeg, A. T., & Zeman, J. (2008). Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. European Journal of Pediatrics. https://doi.org/10.1007/s00431-007-0635-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.